John Dawson
Director/Board Member bij ERGOMED
Vermogen: 516 842 $ op 31-03-2024
Profiel
John Andrew Dawson is currently the Chairman at Virocell Biologics Ltd., the Director at Oxford Biomedica (UK) Ltd., the Senior Independent Director at Ergomed Plc, and the Non Executive Director at Chuangsheng Qiao Kang Pharmaceutical Co., Ltd.
He previously served as the Executive Director at Oxford Biomedica Plc from 2008 to 2022, the Director-Finance & Administration at Serono Laboratories (UK) Ltd.
from 1991 to 1996, the CFO & Head-Business Development at Cephalon, Inc. from 1996 to 2007, and the Member-Supervisory Board at PAION AG from 2014 to 2019.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
OXFORD BIOMEDICA PLC
0.20% | 15-03-2023 | 203 551 ( 0.20% ) | 516 842 $ | 31-03-2024 |
Actieve functies van John Dawson
Bedrijven | Functie | Begin |
---|---|---|
ERGOMED | Director/Board Member | 09-03-2022 |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system. | Director/Board Member | - |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | Chairman | - |
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd.
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. develops ocular therapeutics and treatments for rare diseases. The private company is based in Beijing, CN. and has subsidiaries in the United States. The CEO of the Chinese company is Darren Mercer. | Director/Board Member | - |
Eerdere bekende functies van John Dawson
Bedrijven | Functie | Einde |
---|---|---|
OXFORD BIOMEDICA PLC | Chief Executive Officer | 28-01-2022 |
PAION AG | Director/Board Member | 22-05-2019 |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Director of Finance/CFO | 01-01-2007 |
Serono Laboratories (UK) Ltd. | Director of Finance/CFO | 01-01-1996 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
PAION AG | Health Technology |
OXFORD BIOMEDICA PLC | Health Technology |
ERGOMED | Commercial Services |
Bedrijven in privébezit | 5 |
---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system. | Health Technology |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | Health Technology |
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd.
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. develops ocular therapeutics and treatments for rare diseases. The private company is based in Beijing, CN. and has subsidiaries in the United States. The CEO of the Chinese company is Darren Mercer. | Commercial Services |
Serono Laboratories (UK) Ltd. |